Radiopharmaceutical composition
By using L-arginine, L-histidine and surfactant in liquid pharmaceutical compositions, the radioadsorption problem on the storage container during the preparation of radionuclide-labeled antibodies was solved, and the stability and efficacy of the preparation were improved.
CN120129534APending Publication Date: 2025-06-10NIHON MEDI PHYSICS CO LTD
15 Cites 0 Cited by
Patent Information
- Application Number
- CN202380075062.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-26
- Filing Date
- 2023-10-25
- Publication Date
- 2025-06-10
AI Technical Summary
Technical Problem
In the prior art, the preparation of radionuclide-labeled antibodies has problems with radioadsorption on storage containers, which affects the efficacy and preparation quality.
Method used
By including L-arginine, L-histidine and surfactant in the liquid pharmaceutical composition, the prepared pharmaceutical composition can reduce radioactive adsorption on the storage container.
Benefits of technology
It effectively inhibits the adsorption of radionuclides on the storage container, ensuring the stable quality and efficacy of the preparation.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a liquid pharmaceutical composition containing a complex of a radionuclide and an antibody as an active ingredient. The present invention relates to a composition comprising an antibody that specifically binds to mucoprotein subtype 5AC, the concentration of the antibody in the composition being 0.1 mg / mL or more and 5 mg / mL or less, and the composition being characterized by comprising L-arginine, L-histidine, and a surfactant. The radioactive adsorption of the pharmaceutical composition on a storage container is reduced.
Need to check novelty before this filing date? Find Prior Art